Abstract
Laminin-332 and α6β4 integrin is major hemidesmosome components in the skin. As many studies have shown that laminin-332 and α6β4 integrin play important roles in tumor progression via activation of phosphatidylinositol-3 kinase signaling, understanding of the molecular mechanisms of them could lead to a new drug for cancer therapy.
Keywords: Laminin-332, α6β4 integrin, basement membrane, extracellular matrix, tumor, cell migration, cell adhesion, ErbB2
Mini-Reviews in Medicinal Chemistry
Title: Roles of Laminin-332 and α6β4 Integrin in Tumor Progression
Volume: 9 Issue: 11
Author(s): Y. Kariya, Y Kariya and J. Gu
Affiliation:
Keywords: Laminin-332, α6β4 integrin, basement membrane, extracellular matrix, tumor, cell migration, cell adhesion, ErbB2
Abstract: Laminin-332 and α6β4 integrin is major hemidesmosome components in the skin. As many studies have shown that laminin-332 and α6β4 integrin play important roles in tumor progression via activation of phosphatidylinositol-3 kinase signaling, understanding of the molecular mechanisms of them could lead to a new drug for cancer therapy.
Export Options
About this article
Cite this article as:
Kariya Y., Y Kariya and Gu J., Roles of Laminin-332 and α6β4 Integrin in Tumor Progression, Mini-Reviews in Medicinal Chemistry 2009; 9 (11) . https://dx.doi.org/10.2174/138955709789878114
DOI https://dx.doi.org/10.2174/138955709789878114 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Bioactive as a Potential Therapeutic Approach for the Management of Cyclophosphamide-induced Cardiotoxicity
Current Topics in Medicinal Chemistry Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Malignant Hypercalcemia
Current Medicinal Chemistry Recent Advances in the Diagnosis and Therapy of Primary Adrenal Insufficiency
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine Engineered Biosynthesis of Medicinally Important Plant Natural Products in Microorganisms
Current Topics in Medicinal Chemistry New Improved Drug Delivery Technologies for Pentacyclic Triterpenes: A Review
Protein & Peptide Letters Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine Laparoscopic Approach for Surgical Staging in Early Endometrial Cancer
Current Women`s Health Reviews Polyphenols Counteract Tumor Cell Chemoresistance Conferred by Multidrug Resistance Proteins
Anti-Cancer Agents in Medicinal Chemistry The Influence of Wuzhi Capsule on the Pharmacokinetics of Cyclophosphamide
Recent Patents on Anti-Cancer Drug Discovery Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway
Anti-Cancer Agents in Medicinal Chemistry Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Current Drug Therapy Viral Elements Sense Tumorigenic Processes:Approaching Selective Cancer Therapy
Mini-Reviews in Medicinal Chemistry In Vivo Bio-imaging Using Chlorotoxin-based Conjugates
Current Pharmaceutical Design Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design Optical and Multimodal Peptide-Based Probes for In Vivo Molecular Imaging
Anti-Cancer Agents in Medicinal Chemistry A hypothesis for the role of RECK in angiogenesis
Current Vascular Pharmacology The Design of Drug Candidate Molecules as Selective Inhibitors of Therapeutically Relevant Protein Kinases
Current Medicinal Chemistry Radiolabeled Compounds in the Development of Cytotoxic Agents
Current Pharmaceutical Design